Hemophilia

Last updated: March 27, 2023

Hemophilia

Modulo 3 BPT

Modulo 3 BPT

Nuclear structure
DNA structure
Transcription of DNA
Translation of mRNA
Gene regulation
Epigenetics
Amino acids and protein folding
Protein structure and synthesis
Nucleotide metabolism
DNA replication
Lac operon
DNA damage and repair
Cell cycle
Mitosis and meiosis
DNA mutations
Lesch-Nyhan syndrome
Orotic aciduria
Adenosine deaminase deficiency
Xeroderma pigmentosum
Li-Fraumeni syndrome
Bloom syndrome
Fanconi anemia
McCune-Albright syndrome
Acute radiation syndrome
Purine and pyrimidine synthesis and metabolism disorders: Pathology review
Polymerase chain reaction (PCR) and reverse-transcriptase PCR (RT-PCR)
Gel electrophoresis and genetic testing
ELISA (Enzyme-linked immunosorbent assay)
Karyotyping
DNA cloning
Fluorescence in situ hybridization
Mendelian genetics and punnett squares
Hardy-Weinberg equilibrium
Inheritance patterns
Independent assortment of genes and linkage
Evolution and natural selection
Down syndrome (Trisomy 21)
Edwards syndrome (Trisomy 18)
Patau syndrome (Trisomy 13)
Fragile X syndrome
Huntington disease
Myotonic dystrophy
Friedreich ataxia
Turner syndrome
Klinefelter syndrome
Prader-Willi syndrome
Angelman syndrome
Beckwith-Wiedemann syndrome
Cri du chat syndrome
Williams syndrome
Alagille syndrome (NORD)
Achondroplasia
Polycystic kidney disease
Familial adenomatous polyposis
Familial hypercholesterolemia
Hereditary spherocytosis
Marfan syndrome
Multiple endocrine neoplasia
Neurofibromatosis
Tuberous sclerosis
von Hippel-Lindau disease
Albinism
Cystic fibrosis
Gaucher disease (NORD)
Glycogen storage disease type I
Glycogen storage disease type II (NORD)
Glycogen storage disease type III
Glycogen storage disease type IV
Glycogen storage disease type V
Hemochromatosis
Mucopolysaccharide storage disease type 1 (Hurler syndrome) (NORD)
Krabbe disease
Leukodystrophy
Niemann-Pick disease types A and B (NORD)
Niemann-Pick disease type C
Primary ciliary dyskinesia
Phenylketonuria (NORD)
Sickle cell disease (NORD)
Tay-Sachs disease (NORD)
Alpha-thalassemia
Beta-thalassemia
Wilson disease
Alport syndrome
X-linked agammaglobulinemia
Fabry disease (NORD)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Hemophilia
Mucopolysaccharide storage disease type 2 (Hunter syndrome) (NORD)
Muscular dystrophy
Ornithine transcarbamylase deficiency
Wiskott-Aldrich syndrome
Mitochondrial myopathy
Autosomal trisomies: Pathology review
Muscular dystrophies and mitochondrial myopathies: Pathology review
Miscellaneous genetic disorders: Pathology review
Blood histology
Blood components
Erythropoietin
Blood groups and transfusions
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Role of Vitamin K in coagulation
Clot retraction and fibrinolysis
Iron deficiency anemia
Sideroblastic anemia
Anemia of chronic disease
Lead poisoning
Hemolytic disease of the newborn
Autoimmune hemolytic anemia
Pyruvate kinase deficiency
Paroxysmal nocturnal hemoglobinuria
Aplastic anemia
Megaloblastic anemia
Folate (Vitamin B9) deficiency
Vitamin B12 deficiency
Diamond-Blackfan anemia
Acute intermittent porphyria
Porphyria cutanea tarda
Vitamin K deficiency
Bernard-Soulier syndrome
Glanzmann's thrombasthenia
Hemolytic-uremic syndrome
Immune thrombocytopenia
Thrombotic thrombocytopenic purpura
Von Willebrand disease
Disseminated intravascular coagulation
Heparin-induced thrombocytopenia
Antithrombin III deficiency
Factor V Leiden
Protein C deficiency
Protein S deficiency
Antiphospholipid syndrome
Hodgkin lymphoma
Non-Hodgkin lymphoma
Chronic leukemia
Acute leukemia
Myelodysplastic syndromes
Polycythemia vera (NORD)
Myelofibrosis (NORD)
Essential thrombocythemia (NORD)
Langerhans cell histiocytosis
Mastocytosis (NORD)
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Coagulation disorders: Pathology review
Platelet disorders: Pathology review
Mixed platelet and coagulation disorders: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Lymphomas: Pathology review
Leukemias: Pathology review
Plasma cell disorders: Pathology review
Myeloproliferative disorders: Pathology review
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Prostate cancer
Benign prostatic hyperplasia
Testicular cancer
Ovarian surface epithelial tumors
Ovarian germ cell tumors
Ovarian sex-cord stromal tumors
Endometrial cancer
Cervical cancer
Breast cancer
Disorders of sex chromosomes: Pathology review
Testicular tumors: Pathology review
Ovarian cysts and tumors: Pathology review
Cervical cancer: Pathology review
Breast cancer: Pathology review
Colorectal cancer
Carcinoid syndrome
Irritable bowel syndrome
Colorectal polyps and cancer: Pathology review
Seizures and epilepsy
Dementia: Pathology review
Movement disorders: Pathology review
Demyelinating disorders: Pathology review
Neuromuscular junction disorders: Pathology review
Adult brain tumors: Pathology review
Inflammatory bowel disease: Pathology review
Bowel obstruction

Transcript

Watch video only

Content Reviewers

The word “hemophilia” is a combination of the Greek words for “blood” and “love”, a way of saying that people with hemophilia “love to bleed”, or rather that it’s hard to stop bleeding. This is because the process called hemostasis, literally meaning to stop the flow of blood, is impaired.

Normally, after a cut and damage to the endothelium, or the inner lining of blood vessel walls, there’s an immediate vasoconstriction or narrowing of the blood vessel which limits the amount of blood flow. After that some platelets adhere to the damaged vessel wall, and become activated and then recruit additional platelets to form a plug. The formation of the platelet plug is called primary hemostasis.

After that, the coagulation cascade is activated. First off in the blood there’s a set of clotting factors, most of which are proteins synthesized by the liver, and usually these are inactive and just floating around the blood. The coagulation cascade starts when one of these proteins gets proteolytically cleaved. This active protein then proteolytically cleaves and activates the next clotting factor, and so on. This cascade has a great degree of amplification and takes only a few minutes from injury to clot formation. The final step is activation of the protein fibrinogen to fibrin, which deposits and polymerizes to form a mesh around the platelets. So these steps leading up to fibrin reinforcement of the platelet plug make up the process called secondary hemostasis and results in a hard clot at the site of the injury.

In most cases of hemophilia there is a decrease in the amount or function of one or more of the clotting factors which makes secondary hemostasis less effective and allows more bleeding to happen.

Now, that coagulation cascade can get started in two ways. The first way is called the extrinsic pathway, which starts when tissue factor gets exposed by the injury of the endothelium. Tissue factor turns inactive factor VII into activated factor VIIa (a for active), and then tissue factor goes on to bind the newly formed factor VIIa to form a complex that turns factor X into active factor Xa with the help of calcium. Factor Xa, with Factor Va as a cofactor, turns factor II (which is also called prothrombin) into factor IIa, also called thrombin. Thrombin then turns factor I (or fibrinogen), which is soluble, into factor Ia (or fibrin), which is insoluble and precipitates out of the blood at the site of injury. Thrombin also turns factor XIII into factor XIIIa which cross links the fibrin to form a stable clot. The second way is called the intrinsic pathway, and it starts when platelets near the blood vessel injury activate factor XII into factor XIIa, which then activates factor XI to factor XIa, which then activates factor IX to factor IXa. And factor IXa and factor VIIIa work together to activate factor X to factor Xa, and from that point it follows the same fate as before, so both the extrinsic and intrinsic pathways basically converge on a single final path called the common pathway. Believe it or not, this is a somewhat simplified version of the coagulation cascade; but, it has all of the key parts needed to understand hemophilia.

Now, an insufficient concentration or decreased activity of any coagulation factor can cause hemophilia, except factor XII deficiency which is asymptomatic. Hemophilia usually refers to inherited deficiencies of coagulation factors, which could be either quantitative or qualitative. By far the most common of these are deficiencies of factor VIII which gives rise to factor VIIIa and is stabilized by another factor called von Willebrand factor, and this deficiency is called hemophilia A (or classic hemophilia). Another common deficiency is deficiency of factor IX, called hemophilia B (which used to be called Christmas disease, named after the first patient who had it, not the holiday). Now, a mimic of hemophilia A is von Willebrand disease, which is an inherited problem with primary hemostasis caused by a deficiency of von Willebrand factor. So in severe von Willebrand factor deficiency, factor VIII gets broken down faster and can become deficient, too.

As opposed to inherited forms of hemophilia, one acquired causes of hemophilia is liver failure since the liver synthesizes factors I, II, V, VII, VIII, IX, X, XI, and XIII. Also, vitamin k deficiency can cause hemophilia, since vitamin k is needed by the liver to synthesize and release factors II, VII, IX, and X. Another cause is autoimmunity against a clotting factor, and finally there’s disseminated intravascular coagulation which consumes coagulation factors.

Now, the mutated genes in hemophilia A are called F8, and in hemophilia B they’re called F9, and these are both on the X chromosome, meaning both conditions are X-linked recessive, so it usually affects men, since they only have one X chromosome and therefore only copy of the F8 and F9 genes. Women with one mutated gene copy have a remaining healthy copy, so they don’t get hemophilia unless X-chromosome inactivation turns off the normal copy in the majority of cells. But generally, women are carriers, while men are symptomatic with the disease.

Signs and symptoms hemophilia A and B are nearly clinically identical, which makes sense since factors VIIIa and IXa work together in the coagulation cascade to activate factor X. Both of these can cause easy bruising (or ecchymosis); as well as hematomas (which are collections of blood outside the blood vessels) that are often deep in muscles; prolonged bleeding after a cut or surgical procedure, for example circumcision; oozing after tooth extractions; gastrointestinal bleeding; hematuria, which is blood in the urine; severe nosebleeds; and hemarthrosis (or bleeding into joint spaces).